Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 56, Issue 2, 2013, Pages 272-282

  Falagas, Matthew E ^a,b,d   Tansarli, Giannoula S ^a   Ikawa, Kazuro ^c   Vardakas, Konstantinos Z ^a,b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b MITERA HOSPITAL   (Greece)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

doripenem; ertapenem; imipenem; meropenem

Indexed keywords

CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONFUSION; CONTINUOUS INFUSION; DATA BASE; DRUG FATALITY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY FAILURE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCOPUS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; PENICILLANIC ACID; PIPERACILLIN; TREATMENT OUTCOME;

EID: 84871803445     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis857     Document Type: Review

References (56)

1. Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med 2009; 24:230-41.
2. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother 2012; 11:779-88.
3. Thiem U, Heppner HJ, Pientka L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging 2011; 28:519-37.
4. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the phar-macodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49:1337-9. (Pubitemid 40463358)
5. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005; 56:388-95. (Pubitemid 41158530)
6. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobac-tam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48:4718-24. (Pubitemid 39577677)
7. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacody-namics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35:156-63.
8. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43:523-7. (Pubitemid 29182302)
9. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-8.
10. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. Does prolonged beta-lactam infusion improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11:181.
11. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:581-9. (Pubitemid 41196757)
12. Mah GT, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 2012; 46:265-75.
13. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005; 25:62-7. (Pubitemid 40023348)
14. Dow RJ, Rose WE, Fox BC, Thorpe JM, Fish JT. Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Pract 2011; 19:413-7.
15. Esterly J, Gilley J, Steadman E, Postelnick M, Scheetz MH. Clinical Outcomes of Subjects Receiving Carbapenems for Gram Negative Blood Stream Infections according to Carbapenem MIC. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2010.
16. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacil-lin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22:471-83. (Pubitemid 34270031)
17. Itabashi S. Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia. Japan J Antibiot 2007; 60:161-70. (Pubitemid 47217242)
18. Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006; 50:3556-61. (Pubitemid 44684865)
19. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-63. (Pubitemid 46147617)
20. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with pipera-cillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33:464-8.
21. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40:219-23. (Pubitemid 43269850)
22. Okimoto N, Ishiga M, Nanba F, et al. Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly. Nihon Kokyuki Gakkai Zasshi 2009; 47:553-7.
23. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion piper-acillin/tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis 2009; 64:236-40.
24. Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51:3304-10. (Pubitemid 350067544)
25. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009; 33:290-1.
26. Lee W, Cao JY, Ong S, Chan K, Kwa A. A Prospective Observational Study of the Clinical Efficacy and Safety of Bolus versus Extended-Infusions of Meropenem in Critically Ill Patients with Gram-Negative Pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2009.
27. Schiller DS, Rezai F, Meadows M, et al. Four-Hour Infusions of Piper-acillin-Tazobactam Improve Outcomes in Critically Ill Patients. Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2010.
28. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006; 28:122-7. (Pubitemid 44108605)
29. Kojika M, Sato N, Hakozaki M, et al. A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time. Jpn J Antibiot 2005; 58:452-7. (Pubitemid 41704081)
30. Pedeboscq S, Dubau B, Frappier S, et al. Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin. Pathol Biol (Paris) 2001; 49:540-7. (Pubitemid 32923037)
31. Yost RJ, Cappelletty DM. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 2011; 31:767-75.
32. Falagas ME, Siempos II, Tsakoumis I. Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem. Scand J Infect Dis 2006; 38:807-10. (Pubitemid 44304973)
33. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal mero-penem concentrations to treat multi-drug resistant Pseudomonas aeru-ginosa septic shock. Antimicrob Agents Chemother 2012; 56:2129-31.
34. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; 11: CD005197.
35. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29:548-60. (Pubitemid 46372104)
36. Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clinic Proceedings 2012; 87:349-63.
37. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36:S42-50.
38. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 2009; 31:2765-78.
39. Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010; 68:251-8.
40. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64:142-50.
41. Kikuchi E, Kikuchi J, Nasuhara Y, Oizumi S, Ishizaka A, Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother 2009; 53:2799-803.
42. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of mer-openem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49:1881-9. (Pubitemid 40631603)
43. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011; 15:R206.
44. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007; 5:365-83.
45. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9:23-37. (Pubitemid 351233746)
46. Perrott J, Mabasa VH, Ensom MH. Comparing outcomes of merope-nem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother 2010; 44:557-64.
47. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007; 30:11-8. (Pubitemid 46874893)
48. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 2005; 11 (Suppl 5):4-16. (Pubitemid 41341707)
49. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7. (Pubitemid 37345702)
50. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost analysis of continuous versus intermittent infusion of piper-acillin- tazobactam: a time-motion study. Am J Health Syst Pharm 2003; 60:2321-7. (Pubitemid 44712873)
51. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27. (Pubitemid 39077923)
52. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeru-ginosa bacteremia. PLoS One 2011; 6:e26470.
53. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2:231-42. (Pubitemid 34464753)
54. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.
55. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic mono-therapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57:176-89. (Pubitemid 43160156)
56. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS 2nd. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011; 31:598-608.